The Development of a Community Pharmacy-Based Intervention to Optimize Patients’ Use of and Experience with Antidepressants: A Step-by-Step Demonstration of the Intervention Mapping Process

Pharmacy

Tania Santina¹  Laurence Guillaumie¹  Jean-Pierre Grégoire²  Sophie Lauzier²  Jocelyne Moisan²  Denis Villeneuve³  Hélène Gagnon⁴ 

[1] Faculty of Nursing, Université Laval, Pavillon Ferdinand-Vandry, 1050, Avenue de la Médecine, Quebec City, QC G1V 0A6, Canada;Faculty of Pharmacy and Centre de Recherche du CHU de Québec-Université Laval, Hôpital Saint-Sacrement, 1050 Chemin Ste-Foy, Quebec City, QC G1S 4L8, Canada;Panacée Conseil, Quebec City, QC G2J 0A2, Canada;Quebec City, QC G3B 1Y5, Canada;

关键词: Intervention Mapping;    program development;    antidepressant drugs;    anxiety disorder;    mood disorder;    community pharmacy services;    patient education;    patient satisfaction;    medication adherence;   

DOI  :  10.3390/pharmacy6020039

来源: DOAJ

【 摘 要 】

Objective: To describe the development of a community pharmacy-based intervention aimed at optimizing experience and use of antidepressants (ADs) for patients with mood and anxiety disorders. Methods: Intervention Mapping (IM) was used for conducting needs assessment, formulating intervention objectives, selecting change methods and practical applications, designing the intervention, and planning intervention implementation. IM is based on a qualitative participatory approach and each step of the intervention development process was conducted through consultations with a pharmacists’ committee. Results: A needs assessment was informed by qualitative and quantitative studies conducted with leaders, pharmacists, and patients. Intervention objectives and change methods were selected to target factors influencing patients’ experience with and use of ADs. The intervention includes four brief consultations between the pharmacist and the patient: (1) provision of information (first AD claim); (2) management of side effects (15 days after first claim); (3) monitoring treatment efficacy (30-day renewal); (4) assessment of treatment persistence (2-month renewal, repeated every 6 months). A detailed implementation plan was also developed. Conclusion: IM provided a systematic and rigorous approach to the development of an intervention directly tied to empirical data on patients’ and pharmacists’ experiences and recommendations. The thorough description of this intervention may facilitate the development of new pharmacy-based interventions or the adaptation of this intervention to other illnesses and settings.

【 授权许可】

Unknown